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ABSTRACT – Glioblastoma is a devastating disease of the brain and is the most common 
malignant primary brain tumour in adults. The prognosis for patients is very poor with median time 
of survival after diagnosis measured in months, due in part to the tumours being highly aggressive 
and often resistant to chemotherapies. Alongside the ongoing research to identify key factors 
involved in tumour progression in glioblastoma, medicinal chemistry approaches must also be used 
in order to rapidly establish new and better treatments for brain tumour patients. Using a 
computational similarity search of the ZINC database, alongside traditional analogue design by 
medicinal chemistry intuition to improve the breadth of chemical space under consideration, six 
new hit compounds (14, 16, 18, 19, 20 and 22) were identified possessing low micromolar activity 
against both established cell lines (U87MG and U251MG) and patient-derived cell cultures 
(IN1472, IN1528 and IN1760). Each of these scaffolds provides a new platform for future 
development of a new therapy in this area, with particular promise shown against glioblastoma 
subtypes that are resistant to conventional chemotherapeutic agents.  
 
Introduction 
Glioblastoma are the most common form of malignant brain tumours in adults and account for 12-
15% of all primary intracranial neoplasms, and as aggressive cancers, are often resistant to 
treatment. The median survival time is 6 months overall with only 28% of glioblastoma patients 
surviving for more than one year, and only 3% of patients surviving more than three years.1 Whilst 
the prognosis for patients is generally very poor, the best standard treatment is currently surgical 
resection followed by concomitant radiotherapy to the resection site and chemotherapy with 
temozolomide (Figure 1), in the so-called Stupp protocol.2 Unfortunately, such a demanding 
treatment regime only leads to a mean survival of 14.6 months and a two year survival of 26.5%, 
statistics which highlight that crucial investment is needed in the search for improved treatments, 
not only to improve survival times per se, but to improve survival along with a better quality of life. 
Our initial studies in this area demonstrated that certain 2-arylindoles (e.g. 1 and 2, Figure 1) 
have anti-glioblastoma activity.3 In the case of 1, the mechanism of this activity is consistent with  
the generation of reactive oxygen species (ROS) followed by autophagic cell death, which in some 
cases gave low micromolar EC50 values against patient-derived short-term cell cultures.3, 4 The 
research described herein expands on our previous programme of work and leads to the discovery 
of new and possibly improved scaffolds for further development into much needed glioblastoma 
treatments. Bond dissociation enthalpies (BDEs) were calculated using density functional theory 
(DFT), as a widely used parameter to measure the ease and stability of radical formation for a 
species, in an attempt to rationalise the structure-activity relationships in terms of a ROS 
mechanism.5-7 
The innate heterogeneity of glioblastoma is well-documented with individual tumours 
harbouring a wide spectrum of different genetic abnormalities.8, 9  This molecular diversity accounts 
for the differential efficacy of cytotoxic agents in glioblastoma patients; for example, mutation of 
the TP53 tumour suppressor gene and hypermethylation the DNA repair gene MGMT, are 
associated with increased sensitivity to drugs such as CCNU, temozolomide and vincristine.10-12 
In the present study, the anti-tumour activity of compounds were assessed in 5 glioblastoma 
cell cultures comprising 2 established cell lines (U87MG and U251MG) and 3 patient-derived 
short-term cell cultures (IN1472, IN1528 and IN1760).  U87MG and IN1760 were TP53 wild-type 
whilst the remaining 3 cultures harboured various TP53 mutations. Methylation and transcriptional 
silencing of MGMT was present in 3 cultures (U87MG, U251MG and IN1760).13 In previous 
studies, we have determined the differential responses of these cultures to a number of 
chemotherapeutic compounds which act through diverse mechanisms.  In all cases, IN1760 and 
IN1472 are the most resistant and sensitive cultures respectively, with the remaining 3 cultures 
demonstrating an intermediate response.14 
 
Figure 1. Structure of the first-line treatment temozolomide for malignant brain tumours of the type glioblastoma 
multiforme (GBM), and two 2-aryl indoles from our previous work on anti-glioblastoma lead compounds.3 The work 
described herein is depicted by the box entitled ‘This work’ showing the features of 1 that were studied and some 
selected EC50 values. 
 
Figure 1 outlines our approach towards the investigation of structure-activity relationships between 
this known class of compound (1) and its anti-glioblastoma activity. Due to the inherently non-
exhaustive search of chemical space in our approach, one would not necessarily expect to find a 
compound with exceptional activity but one may expect to find an uncommon fragment, or a 
fragment with development potential, with reasonable activity for further development. This further 
development could then take the shape of a more traditional structure-activity relationship based 
approach, thus allowing the investigation of the more local chemical space of the active drug 
fragment.15 
 
Results and Discussion 
Exploring the 2-phenylindole core of lead compound 1 
 
Figure 2. The series of phenols tested in order to establish the importance of the indole group. 10 is assumed to 
hydrolyse to the phenol in the cell. M and I represent mesomeric and inductive effects, respectively. 
 
 While there are many examples of complex phenols, polyphenols and hydroquinones having 
reasonable anti-proliferative activity,16-18 reports on the cytotoxic activities of simple phenols are 
relatively few in number. Nevertheless, there is some evidence that certain simple phenols do have 
modest cytotoxic activity, and increasing the complexity of the phenols appears to significantly 
improve the activity.19, 20 One of the reasons for the cytotoxic activity of phenolic compounds lies in 
their ability to generate ROS,21 which in turn, relies on their ability to lose both a proton and an 
electron (formally a hydrogen radical) from the hydroxyl group, subsequently forming both reactive 
chain-propagating radicals, and a phenoxyl radical.22 Gas phase bond dissociation enthalpies (BDEs) 
can act as excellent primary indicators of free radical scavenging activity and it has been suggested 
that trends in BDEs are only weakly solvent dependent,5, 23 where DFT calculations have been 
successfully used to compute O-H BDEs for phenolic compounds.5, 24, 25 Calculated BDEs provide a 
useful predictive measure of the relative ease of ROS formation. We calculated a gas phase BDE of 
87.7 kcal/mol for phenol at the B3P86/6-311G**+ level of theory, which is consistent with previous 
reported calculations of this type when compared with experiment.26 As comparisons between 
predicted relative BDE values are more accurate within structurally similar series of compounds, we 
follow suit in our analysis herein. 
Based on such precedent, and our previous results confirming the involvement of ROS,3 
lead compound 1 can be considered to be an ortho-substituted phenol with the indole ring acting as 
a conjugated system to increase radical stabilisation once formed. With this in mind, a small series 
of simple, commercially available phenols were screened (Figure 2) to see if mesomeric (M) and/or 
inductive (I) effects alone could act in the same way as the indole in terms of affecting activities. 
 
 
 
 
 
Compound U87MG U251MG IN1472 IN1528 IN1760 
BDE 
(kcal/mol) 
1 126 (101, 154) 130 (112, 215) >625a 99 (85, 191) 185 (87, 630) 77.1 
3 834 (717, 968) 1229 (966, 1710) 1731 (1261, 2990) 747 (543, 1203) >4000a 87.7 
4 760 (656, 881) 1205 (889, 1967) 1389 (1156, 1627) 
 
793 (683, 821) > 4000a 91.6 
5 888 (759, 1034) 1251 (994, 1630) n.d. 890 (699, 1136) > 4000a 101.1 
6 n.d.  17 (15, 20) n.d. n.d. n.d. 79.5 
7 n.d. 57 (46, 71) n.d. n.d. n.d. 82.1 
8 492 (436, 555) 1141 (993, 1341) 2021 (1296, 5822) 813 (640, 1084) >4000a 86.8 
9 664 (537, 844) 1565 (1172, 3146) 1436 (1255, 1642) 744 (682, 812) >4000a 85.5 
10 723 (539, 1020) 1341 (988, 2202) 1413 (1221, 1728) 787 (648, 983) >4000a 94.0b 
Table 1. Comparison of EC50 values (𝜇M) between a series of simple phenols (the values in parentheses represent the 
95% confidence interval level, 95% CI), together with calculated O-H BDEs at the B3P86/6-311+G** level of theory. 
n.d. = not determined in this batch. The best EC50 values are highlighted in bold. aEC50 not reached. bBDE for salicylic 
acid. EC50 values were calculated using a sulphorhodamine B (SRB) assay and represent anti-proliferative activity.  
 
The activities of this series of simple phenols 3-10 are shown in Table 1 alongside 1 for 
comparison. Reviewing the activities of the individual phenols against the individual cell cultures 
(U87MG, U251MG, IN1472, IN1528 and IN1760) generally shows that there isn’t much variation 
in activity, in a broader sense, with only modest activity observed, with the exception of the two 
hydroquinones (6 and 7) against the U251MG cell lines (EC50s = 17 and 57 µM respectively). 
Whilst this data suggests that no clear conclusion can be drawn for the relative activities of these 
phenols and hydroquinones against GBM, hydroquinones are known to be involved in redox 
cycling in other systems,27, 28 and so such compounds warrant further study in the area of brain 
tumour research. Especially, since it is known that such compounds can be toxic if not-targeted to 
the tumour site directly, and so further study would focus on finding analogues that could 
demonstrate selectivity over non-cancerous cells. On the contrary, with the exception this time of 
U251MG, in general 1 seems to have significantly higher anti-proliferative activity than the phenols 
against the other four cultures. The magnitude of this difference in activity suggests that, in this 
context at least, either the ortho-indole group is an excellent substituent for the phenol group, or that 
there is a unique and perhaps synergistic effect between the indole and phenol moieties. Although 
there doesn’t appear to be a strong correlation between BDE and EC50 (Table 1), the three most 
active compounds (1, 6 and 7) do have the lowest BDE values of all those tested. The almost 
complete lack of activity in the IN1760 culture is representative of its extremely resistant nature to 
chemotherapeutic drugs. 
 
The importance of the phenol group in 1 
 
Figure 3. Analogues used to probe the importance of the phenol group. 
 
In order to determine the significance of the phenol group in 1, a series of closely related 
analogues (Figure 3) were developed (the synthesis of all compounds prepared can be found in the 
Supporting Information). These analogues included a compound without the phenol group (indole), 
an aniline analogue (11), a compound without the phenolic-OH group (2-phenylindole, 12), and a 
methoxy derivative, 13. 
 
Compound U87MG U251MG IN1472 IN1528 IN1760 
BDE 
(kcal/mol) 
1 126 (101, 154) 130 (112, 215) >625 a 99 (85, 191) 185 (87, 630) 77.1 
Indole >625 a >625 a >625 a >625 a >625 a No BDE 
11 257 (82, 525) 328 b 155 (82, 828) 153 (59, 256) n.d. 84.8 
12 >625 a >625 a >625 a >625 a >625 a No BDE 
13 >625 a  n.d. n.d. n.d. n.d. No BDE 
Table 2. Comparison of EC50 values (𝜇M) between 1 and analogues probing the significance of the phenol group (95% 
CI), together with calculated O-H BDEs at the B3P86/6-311+G** level of theory. The best EC50 values are highlighted 
in bold. n.d. = not determined in this batch. a EC50 not reached. b CI not calculable. 
  
This is an interesting data set since the response is broadly similar across cultures, implying 
that the cytotoxic effects, or lack of, are independent of genetic background. Importantly, upon 
removal of either the hydroxyl group (analogue 12), the whole phenolic substituent (indole) or 
masking it (13), the EC50 value rises to above what can be determined under the assay conditions 
employed (Table 2). Although the extent of activity loss cannot be determined absolutely, it can be 
confidently asserted that the phenol is essential for activity, yet must be sufficiently substituted to 
exert its effect (see activity of phenol in Table 1). 
 When comparing the activity of 1 with its aniline analogue (11), across all four cell cultures 
that they were compared against, 1 has consistently higher activity (with the exception of IN1472), 
although both compounds have only modest activity, possibly attributed to the fact that only these 
two compounds have a calculated BDE. Under normal practises, this result would encourage similar 
analogues of 1 and 11 to be studied, including heteroatom analogues such as indolylthiophenols or 
indolylphenylphosphines, however, such an in-depth approach was not the focus of the study here. 
 
A Similarity Searching Approach 
One of the key steps in the early stage of drug development is finding active hits which can 
serve as molecules that will be further optimised into potential drug candidates. In order to identify 
such alternative scaffolds that could potentially act through a similar mechanism, we carried out a 
computational similarity study, whereby a large database could be interrogated, thus expanding the 
area of chemical space being explored beyond that which may be familiar to a medicinal chemists, 
to those which are documented in a curated repository or database. The choice of database is an 
important one and can strongly influence the results of a similarity search.29 Accordingly, in order 
to discover otherwise non-obvious structural analogues of our lead compound/fragment (1), a 
similarity search was carried out. 
On balance, the most suitable database considered for this work was the ZINC database.30 It 
is of particular interest since the data is curated into subsets, which can, by judicious selection of the 
subsets, improve the efficiency of the search process. In this work, the subset of data that has been 
opted for was the fragment-like subset of compounds (molecular weight ≤ 250, log P ≤ 3.5, number 
of rotatable bonds ≤ 5) which were advertised as currently in stock, a subset that included almost 
800,000 entries. Similarity screening was conducted on this database using ShaEP (a software tool 
for a rigid-body superimposition and similarity evaluation of ligand-sized molecules)31 but to 
account for the fact that ShaEP handles structures as rigid bodies, up to three low energy 
conformations of the compounds were pre-generated using BALLOON,32 producing a total of over 
1.4 million structures for interrogation. From preliminary computational calculations, what a 
medicinal chemist might call very similar from a chemistry perspective (e.g. heteroatom analogues 
or positional isomers ShaEP would consider to have a similarity of around 0.8. The 105 compounds 
with the highest overall similarity value were taken forward as a manageable number of hits to be 
manually inspected in the next step. The structures of these 105 candidate compounds can be seen 
in the Supporting Information. Upon inspection it became apparent that these 105 compounds could 
be grouped based on our lead compound (1) and its accepted mechanism of action being related to 
the formation of a phenol radical for ROS generation.3  
The first and largest group (59 entries) comprised of compounds that had no way of 
generating a phenolic (or analogous) radical, for example, compounds that had no phenol or aniline 
group. Since these compound don’t agree with the current evidence on how our lead compound 
acts,3 they were not included in the work beyond this point. Excluding this class of compounds left 
a further 46 compounds to be considered. 
The next group of compounds were 20 isomers or pseudoisomers of 1. Unsurprisingly, 
compounds in this group typically had the highest similarity score (0.79-0.88). However, this work 
was being done with the intention of encountering analogues which would otherwise not have been 
considered, by investigating a wider range of chemical space as possible, and so compounds in this 
group were also not considered further. 
The third group of compounds (26 entries, some of which are shown in Figure 4) are those 
which may be able to form a conjugated radical (like 1), but have a core other than 2-phenylindole 
(with the exception of 19 which is included here for comparison). Such a scaffold-hopping 
approach has been widely applied by medicinal chemists to discover equipotent compounds with 
novel backbones that have improved properties,15 and using this approach revealed compounds with 
the potential for a phenolic-like radical to be formed. 
Within this third group, a total of 14 different cores other than the 2-phenylindole core of 
lead compound 1 were identified (see Supporting Information for structures), with the 2-
phenylbenzimidazole core occurring far more than any other. 
 
 
Figure 4. The analogues tested with different scaffolds to that of 1. EC50s can be seen in Table 3. 
 
The analogues of compound 1 identified were screened for biological activity are shown in 
Figure 4. The biological data for 14-23 can be seen in Table 3. 
 
 
 
 
  
Compound U87MG U251MG IN1472 IN1528 IN1760 
BDE 
(kcal/mol) 
1 126 (101, 154) 130 (112, 215) >625b 99 (85, 191) 185 (87, 630) 77.1 
14 52 (34, 82) 2257 (1521, 7815) n.d. n.d. >2500b 98.0 
15 >1250a >1250 a >1250 a >1250 a >1250 a 92.5 
16 48 (37, 62) 92 (83, 101) n.d. 104 (87, 123) >1000 b 86.6 
17 n.d. 372 (290, 412) n.d. 361 (130, 818) 236 (154, 377) 87.0 
18 n.d. 102 (76, 126) n.d. 85 (66, 111) 81 (70, 130) 85.1 
19 n.d. 21 (18, 24) n.d. 29 (25, 35) 32 (28, 36) 75.6 
20 n.d. 95 (81, 113) n.d. 120 (38, 429) 231 (120, 1002) 82.9 
21 n.d. 916 (619, 1925) n.d. 744 (459, 1642) 1079 c 90.0 
22 n.d. 23 (19, 27) n.d. 25 (19, 31) 36 c 83.2 
23 n.d. 304 (254, 433) n.d. 193 (87, 848) 371 (216, 858) 85.9 
Table 3. Comparison of EC50 values (𝜇M) between compound 1 and a series of analogues with different scaffolds as 
shown in Figure 4 (95% CI), together with calculated O-H BDEs at the B3P86/6-311+G** level of theory. a EC50 not 
reached as the compound precipitated out of solution >1250 𝜇M. n.d. = not determined in this batch. The best EC50 
values are highlighted in bold. b EC50 not reached. c CI not calculable. 
 
Benzothiazole 15 precipitated out of solution at concentrations greater than 1250 𝜇M and so 
its EC50 could not be calculated. Whereas, comparing benzoxazole 14 and compound 1 reveals that 
overall, 1 has higher activity, with the exception of the U87MG cell line. This seems to indicate that 
the 2-phenylindole core is better than the intuitively highly similar benzoxazole and benzothiazole 
cores as a molecular scaffold for anti-glioblastoma compounds, at least in these cultures. 
 Comparing 1 against its naphthalene analogue (16) shows that the naphthalene analogue has 
higher activity against U87MG and U251MG cell cultures, with 1 only having significantly higher 
activity against IN1760, indicating that the naphthalene analogue appears to be a very active 
compound (the similarity between 1 and 16 being 0.81). This is significant, as it indicates that the 
weakly hydrogen bonding NH group of 1 is not essential for activity (a theory supported by the 
activity observed with 14 against U87MG cultures), and that the role of the scaffold may be limited 
to such effects as radical stabilisation, sterics and/or π-stacking. 
Comparing 1 against 17 on the three cell cultures studied shows that 1 has superior activity 
against all. Again, this effect provides evidence that the ortho-indole group appears to be an 
excellent substituent for phenol, as indicated by the data in Table 1. 
Interestingly, comparing the activities of 16 and 17 suggests that the extended naphthalene 
core is beneficial for activity. Similarly, the para-phenyl phenol analogue (18), highlights possible 
areas for further study in a more detailed approach to SAR. 
Compounds 1 and 20 were chosen for comparison in the hope that these isomers would give 
information about the importance of shape. As previously revealed, 1 behaves as a ROS generator, 
the effects of which can be attenuated by the antioxidant ascorbic acid, a feature that is directly 
linked to the presence of the hydroxyl group.3 In this respect, the electronics of 1 and 20 are 
expected to be similar, as they have the same number of canonical forms to stabilise the proposed 
hydroxyl radical (Figure 5). In the event, the compounds were found to have very similar activities 
against all three cell cultures on which they were compared, with 1 being slightly more active 
against the IN1528 and IN1760 cultures, and 20 being more active against the U251MG culture. 
 
 
Figure 5. The possible locations of a delocalised phenol radical, identified by an asterisk (*), on 1 and 20 (left); and an 
analogue of 1 with reduced conjugation, 24 (right). 
 
Surprisingly, indole 19, which contains a +I methyl group para to the hydroxyl, and thus is 
suitably positioned to stabilise a radical at that position, is extremely active against the short-term 
cell cultures. This particular indole is known to scavenge free radicals in vitro, albeit at lower 
concentrations than used here, and so presumably this increased activity when used at higher 
concentrations is the result of a more toxic, longer-lived radical in the cell.33 
Interestingly, compounds 21 and 22 show drastically different activities. Compound 21 has 
significantly reduced activity against all three cell cultures, presumably the result of a reduction in 
radical stabilisation with the non-conjugated phthalimide ring, whereas 22 has very potent activity 
with values of EC50 ≤ 36 μM for all three cell cultures and is thus more active than its heteroatom 
analogues 14 and 15, as well as compound 1. All these comparisons indicate that specific scaffolds 
can have activity against different glioblastoma cell cultures. Even if the observed activity does not 
occur via the same ROS mechanism, the process of similarity searching has successfully allowed us 
to identify new hit compounds of higher activity than the lead compound. Structurally speaking, the 
six new lead compounds 14, 16, 18, 19, 20 and 22 would appear to be able to support a radical and 
act through a ROS mechanism (supported by their high activities, Table 3).  
 Considering all of this data together, it would seem that the activity of 1 is not highly 
sensitive to three-dimensional shape, as seen with the comparison of 1 and 20. Furthermore, activity 
does not seem particularly sensitive to the bicyclic ring system (see compounds 14, 16, 18, 20 and 
22) either; features which we have identified and which has delivered numerous compounds with 
improved activity compared to 1. However, perhaps of even greater importance is that new hit 
compounds have been identified that are very active against the extremely resistant IN1760 culture 
(compounds 19 and 22). 
Furthermore, compound 23, found during the similarity search mentioned above, is both 
chemically and structurally dissimilar to 1, yet is considered by the ShaEP software to be highly 
similar in terms of both shape and electronics of the system, with an overall similarity score of 
0.785. 
However, compound 23 has only modest activity against the cultures studied. Interestingly, 
however, 23 is much more potent than the related simple phenol guaiacol (8) above (EC50 values for 
U251MG = 1141 𝜇M; IN1528 = 813 𝜇M; and IN1760 = >4000 𝜇M). 
In general, again there is no strong correlation between activity and BDE, but the best two 
compounds identified from the similarity searching approach (19 and 22) have two of the lowest 
BDE values of the new compounds. 
 
Reducing the conjugation of compound 1 
 In order to investigate the necessity of conjugation between the proposed phenol radical and 
the indole motif for radical stabilisation, an analogue with reduced conjugation between the two 
ring systems should be less active if a fully conjugated system is required (24, Figure 5). The BDE 
of 24 was calculated (90.2 kcal/mol) and follows the expected trend compared to the more 
conjugated 1 (77.1 kcal/mol).  In addition to its reduced conjugation, the three-dimensional shape of 
24 is somewhat different to that of 1 due to the loss of planarity inherent in reducing the carbon-
carbon double bond (sp2→sp3). Nevertheless, as has been shown by the analogues depicted in 
Figure 4, activity within this phenolic class of compounds is not highly sensitive to shape, so this 
issue may be moot. 
 In the event, the EC50 values for 24 were: 122 µM (U251MG); 123 µM (IN1528) and 
148µM (IN1760), with 1 having comparable activities against the patient-derived cell cultures. As a 
result, determining the superior anti-glioblastoma agent is difficult based solely on this data alone. 
What can be inferred is that the full conjugation seen in 1, which was originally considered to be 
essential for its activity, is perhaps not the only factor involved in promoting activity. 
 
 
 
 
The effect of O-protected analogues 
 
Figure 6. O-protected analogues. 
 
In previous work, compound 1 was observed to have a rapid onset of activity (<1h).3 The 
compounds shown in Figure 6 were prepared and tested to further understand and mitigate this 
rapid onset of activity of 13 by controlling the release of the active compound through a, 
presumably enzyme-driven, hydrolytic process. The activities of the compounds depicted in Figure 
6 are shown in Table 4. 
 
Compound U251MG IN1528 IN1760 
1 130 (112, 215) 99 (85, 191) 185 
25 39 (30, 47) 38 * n.d. 
26 31 (19, 59) 80 (51, 96) n.d. 
27 38 (28, 59) 29 (8, 37) n.d. 
Table 4. Comparison of EC50 values (𝜇M) between 1 and a series of O-substituted derivatives (95% CI). n.d. = not 
determined in this batch. The best EC50 values are highlighted in bold. * CI not calculable. 
  
Interestingly, all three esters have better activity than compound 1 against the U251MG and 
IN1528 cell cultures, presumably the result of improved cell penetration with the more hydrophobic 
compounds. However, that the compounds result in similar EC50 values eventually suggests that the 
esters are hydrolysed, liberating compound 1.34 
To investigate the possibility of the O-protected analogues of 1 being used as delayed-
release prodrugs, a time course assay for both 1 and its O-heptanoyl analogue (27) was carried out 
on two glioblastoma cell cultures. The results (see Supporting Information) confirmed that 
compound 1 does have a rapid activity against both cell cultures studied, whereas 27 reduced cell 
viability much more gradually. Importantly, both compounds tended towards the same activity over 
24h. This agrees with the hypothesis that the heptanoyl group can be cleaved off to produce 
compound 1, as the activity of compound 27 is ultimately equal to that of compound 1, yet it takes a 
measureable time for the enzymatic cleavage to occur. Presumably, a similar unmasking of the 
phenol group can occur with 13, this time with enzymes that are capable of demethylation, but 
based on the activity observed with 13 this either doesn’t take place, or is slow. 
 
Conclusion 
Five structural features of compound 1 were investigated (Figure 1) where it was found that 
a phenolic (or analogous –NH2) group was required for activity, as removal of this group resulted in 
complete loss of activity. It was also shown that simple phenols (with the exception of 
hydroquinones 6 and 7) had much lower activity than 1, suggesting that the indole moiety has 
significant importance, befitting of its place as a privileged structure.35 Investigating different 
scaffolds yielded some interesting findings too, identifying compounds with improved activities to 
1, indicating that the NH group of the indole is not essential for activity, and that other aromatic 
systems can stabilise the phenoxy radical in addition to indole. Surprisingly, the O-substituted 
analogues showed higher activity than expected.  
 Overall, this approach has identified six new promising compounds (14, 16, 18, 19, 20 and 
22) as superior fragments on which to base the design of new bioactives for glioblastoma, and 
future work will utilise these compounds as leads. A significant breadth of chemical space has been 
explored so far within this work, however the local chemical space of any of the active functional 
analogues of compound 1 has not been probed to any appreciable depth. Future work will therefore 
also focus on refining and developing the structures of these newly identified compounds in order to 
improve their activities and physicochemical properties via an in-depth SAR approach. 
That said, glioblastoma is a very heterogeneous tumour, therefore one would expect 
different compounds to have different activities in different biological samples generated from it. 
As such, compounds that have similarly high activities against all (or most) of the cultures tested 
could in fact be highlighting structures that facilitate anti-proliferative activity via a universal 
mechanism which is independent of the genetic profile of the individual tumour. Such universally 
acting compounds would be much more useful in a clinical setting and would reduce the need for 
tumour profiling and patient stratification. 
 
Experimental Section 
BDE Calculations 
DFT geometry optimisations of compounds and their corresponding radicals were carried out using 
the B3P86 functional,36, 37 previously revealed as effective in calculations of this type,24, 38 in 
conjunction with the 6-311+G(d,p) basis set.39-42 The optimised structures were confirmed as real 
minima by vibrational frequency analysis (no imaginary frequencies) and zero-point energy (ZPE) 
corrections were obtained. The spin restricted open-shell (RODFT) approach was used for 
optimisation of the radical species. While restricted open shell calculations incorrectly prevent spin 
polarisation, there is no spin contamination as in unrestricted open shell calculations and the correct 
<S2> for the corresponding wavefunctions are obtained (i.e. 0.75 for radicals).  The total enthalpy of 
a species X, H(X), at temperature T (298.15 K) was calculated from the expression: 
 
H(X) = ESCF + ZPE + U + RT                                           Eq. (1) 
 
where ESCF is the electronic self-consistent field energy, ZPE is the zero-point energy, and 𝑈 the 
combined translational, rotational and vibrational contributions. RT represents the PV-work term and 
is added to convert the energy to the enthalpy. Vibrational frequencies were used unscaled to obtain 
the zero-point vibrational energies (ZPEs) and the vibrational contributions to the enthalpy. Using the 
total enthalpies, BDE values were determined as follows: 
 
                                BDE = H(RO·) + H(H·)  - H(ROH)                              Eq. (2) 
 
All the DFT calculations were performed Jaguar v9.0 (Schrodinger LLC, New York, NY, 2017) 
 
Generic information 
Reactions were followed by analytical thin layer chromatography (TLC) using plastic-backed TLC 
plates coated in silica G/UV254, run in a variety of solvent systems and visualised with a UV light at 
254 nm, p-anisaldehyde stain and/or potassium permanganate stain. Commercially available 
solvents and reagents were purchased from Fisher, Sigma Aldrich, TCI and Fluorochem and were 
used without further purification unless specified in the syntheses. Flash column chromatography 
was carried out on Davisil silica 60 Å (40 – 63 µm) under bellows pressure. High resolution mass 
spectra were obtained at the EPSRC UK National Mass Spectrometry Facility in Swansea 
University’s College of Medicine using a LTQ Orbitrap XL™ Hybrid Ion Trap-Orbitrap Mass 
Spectrometer coupled to a TriVersa NanoMate® ESI source. Low resolution mass spectra were 
obtained on a Thermo Finnigan LCQ Advantage MAX using electrospray ionisation (ESI) or 
atmospheric pressure chemical ionisation (APCI). 1H and 13C NMR were carried out on a Bruker 
Fourier 300 (300 MHz) or a Bruker Advance III 400 (400 MHz) with broad band decoupling, and 
all chemical shifts (δ) quoted in parts per million (ppm) relative to the residual solvent peaks of 
CHCl3 (δH 7.26, δc 77.16) or d5-DMSO (δH 2.50, δC 39.52). J values are given in Hertz (Hz).  
Infrared spectra were recorded on a solid sample using a Thermo Nicolet IR-200 FT-IR. Melting 
points are uncorrected, and were recorded using a Stuart SMP10. Preparative liquid 
chromatography was carried out on a Teledyne Isco CombiFlash® Rf 200. Elemental analysis was 
carried out using a Thermo Scientific™ FLASH 2000 CHNS/O Analyser. Petroleum ether refers to 
the fraction that boils between 40-60 oC. Assignments of NMR spectra was aided with the use of 
DEPT-135, and in some cases HSQC and HMBC. 
 
Compound synthesis 
 
2-(1H-Indol-2-yl)phenol (1)43 
 
3-12, 17, 18, 21-23 and indole were purchased from Sigma-Aldrich, UK. 
 
Compounds 14 and 15 were purchased from TCI Chemicals, UK. 
 
2-(20-Methoxyphenyl)-1H-indole (13)3 
 
2-(Naphthelen-7-yl) phenol (16) 
To a flask containing water (5 mL), was added 2-bromonaphthalene (331 mg, 1.6 mmol), 
2-hydroxyphenylboronic acid (500 mg, 2.4 mmol), diisopropylamine (DIPA, 0.45 mL, 3.2 mmol) 
and palladium (II) acetate (12.3 mg, 0.25 mol%).  The reaction was heated to reflux for 3.5 hours, 
and was allowed to cool to room temperature before being diluted with brine (40 mL) and extracted 
with ethyl acetate (5 × 20 mL).  The reaction was filtered through Celite®, and the filtrate dried 
(MgSO4) and filtered.  The crude reaction was purified via flash column chromatography on silica 
gel (5:1 petroleum ether: ethyl acetate) to afford the title compound as a pale yellow solid (288 mg, 
82% yield).  M.p. 93-96 oC;  Rf = 0.37 (5:1 petroleum ether: ethyl acetate);  1H NMR (300 MHz, 
CDCl3): δH = 8.03-7.97 (2H, m, Ar), 7.96-7.88 (2H, m, Ar), 7.66-7.54 (3H, m, Ar), 7.43-7.30 (2H, 
m, Ar), 7.13 (2H, m, Ar), 5.42 (1H, s, OH);  13C NMR (75 MHz, CDCl3): δC = 152.7 (Ar, Cq), 134.6 
(Ar, Cq), 133.7 (Ar, Cq), 132.8 (Ar, Cq), 130.3 (Ar, CH), 129.4 (Ar, CH), 129.2 (Ar, CH), 128.2 (Ar, 
Cq), 128.1 (Ar, CH), 127.9 (Ar, CH), 127.9 (Ar, CH), 127.2 (Ar, CH), 126.7 (Ar, CH), 126.5 (Ar, 
CH), 121.1 (Ar, CH), 116.0 (Ar, CH);  IR (neat, cm-1) ν = 3520 (OH stretch), 750 (Aromatic C-C 
bend);  MS (EI): m/z 220 (M);  HRMS found: [M+H]+ 221.0960, C16H12O+H+ requires 221.0961. 
 
2-(1H-Indol-2-yl)-4-methylphenol (19) 
Phenylhydrazine (108 mg, 1.00 mmol), 2-hydroxy-5-methylacetophenone (216 mg, 1.44 mmol) and 
p-toluenesulfonic acid (20 mg, 0.10 mmol) were heated under microwave irradiation at 200°C for 20 
minutes. The crude reaction was purified via flash column chromatography on silica gel (5:1 
petroleum ether: ethyl acetate) to afford the title compound as a dark solid (68 mg, 31% yield).  Rf = 
0.09 (5:1 petroleum ether: ethyl acetate);  1H NMR (300 MHz, CDCl3): δH = 9.28 (1H, br s, NH), 
7.65 (1H, d, J = 8.0 Hz, Ar), 7.51 (1H, d, J = 1.5 Hz, Ar), 7.42 (1H, d, J = 8.0 Hz, Ar), 7.20 (1H, td, 
J = 7.5, 1.0 Hz, Ar), 7.13 (1H, td, J = 7.5, 1.0 Hz, Ar), 7.01 (1H, dd, J – 8.0, 2.0 Hz, Ar), 6.78 – 6.88 
(2H, m, Ar), 5.43 (1H, br s, OH), 2.25 (3H, s, CH3);  13C NMR (100 MHz, CDCl3): δC = 150.1 (Cq, 
Ar), 136.6 (Cq, Ar), 135.3 (Cq, Ar), 130.9 (Cq, Ar), 129.6 (CH, Ar), 128.7 (CH, Ar), 128.7 (Cq, Ar), 
122.3 (CH, Ar), 120.6 (CH, Ar), 120.2 (CH, Ar), 119.0 (Cq, Ar), 116.6 (CH, Ar), 111.1 (CH, Ar), 
100.2 (CH, Ar), 20.7 (CH3); MS (EI): m/z 224 ([M+H]+);  HRMS found: [M-H]- 222.0924, 
C15H13NO-H+ requires 222.0924. 
 
2-(1H-Indol-3-yl)phenol (20) 
2-Benzyloxyphenylacetic acid (983 mg, 4.06 mmol) was stirred in methanol (45 mL) and sulfuric 
acid (2 drops) at room temperature for 72 hours to yield methyl 2-(2-(benzyloxy)phenyl)acetate. Rf 
= 0.60 (3:1 petroleum ether: ethyl acetate); 1H NMR (300 MHz, CDCl3): δH = 7.45 – 7.29 (5H, m, 
Ar), 7.29 – 7.18 (2H, m, Ar), 6.94 (2H, m, Ar), 5.08 (2H, s, O-CH2-Ar), 3.70 (2H, s, Ar-CH2-
COOMe), 3.64 (3H, s, CH3). 
The crude methyl ester was reduced to the alcohol by stirring in THF (dry, 15 mL) at 0oC and 
adding LiAlH4 (308 mg, 8.11 mmol) under an atmosphere of nitrogen.  The ice bath was then 
removed, and the reaction was stirred at room temperature for 90 minutes.  The reaction was quenched 
with NaOH(aq) (10 mL, 0.1 M).  The crude product was extracted with ethyl acetate (3 × 10 mL), and 
the combined organic layers were dried over MgSO4 and filtered before being concentrated in vacuo 
to yield crude 2-(2-(benzyloxy)phenyl)ethanol. Rf = 0.22 (3:1 petroleum ether: ethyl acetate); 1H 
NMR (300 MHz, CDCl3): δH = 7.49 – 7.32 (5H, m, Ar), 7.28 – 7.19 (2H, m, Ar), 7.00 - 6.91 (2H, m, 
Ar), 5.10 (2H, s, Ar-CH2-OAr), 3.87 (2H, t, J = 6.5, CH2-OH), 2.98 (2H, t, J = 6.5 Hz, 
Ar-CH2-CH2OH), 1.95 (1H, br s, OH). 
The crude alcohol was oxidised to the aldehyde by stirring with pyridinium chlorochromate 
(1.31 g, 6.08 mmol) in CH2Cl2 (40 mL) in the presence of crushed molecular sieves (650 mg) at room 
temperature for 22 hours.  The solvent was removed in vacuo, and the crude reaction was dissolved 
in diethyl ether (40 mL), before being filtered through Celite®.  The crude reaction was purified by 
flash column chromatography (19:1 petroleum ether: ethyl acetate) to yield 0.70 g of an 84:16 ratio 
of products, which included 468 mg (51% yield over 3 steps) of the major product 
2-(2-(benzyloxy)phenyl)acetaldehyde.  Rf = 0.61 (3:1 petroleum ether: ethyl acetate); 1H NMR (300 
MHz, CDCl3): δH = 9.72 (1H, t, J = 2.0 Hz, CHO), 7.45 – 7.24 (6H, m, Ar), 7.20 - 7.14 (1H, m, Ar), 
7.00 - 6.93 (2H, m, Ar), 5.08 (2H, s, O-CH2-Ar), 3.70 (2H, d, J = 2.0 Hz, CH2-CHO). 
The mixture of aldehydes (0.70g, of which 468 mg, 2.07 mmol was the desired aldehyde) was added 
to a microwave vial with phenyl hydrazine (336 mg, 3.11 mmol) and p-toluenesulfonic acid (40 mg, 
0.21 mmol) and heated at 200 oC for 20 minutes.  The crude product was purified by flash column 
chromatography on silica gel (19:1  9:1 petroleum ether: ethyl acetate) to yield 3-(2-
(benzyloxy)phenyl)-1H-indole (200 mg, 32% yield).  1H NMR (300 MHz, CDCl3): δH = 8.12 (1H, br 
s, NH), 7.95 (1H, d, J = 7.5 Hz, Ar), 7.79 (1H, dd, J = 7.5, 1.5 Hz, Ar), 7.53 (1H, d, J = 2.5 Hz, Ar), 
7.42 – 7.11 (11H, m, Ar), 5.14 (2H, s, CH2). 
Methanol (10 mL) was added to a two-necked flask containing 3-(2-(benzyloxy)phenyl)-1H-
indole (200 mg, 0.67 mmol) and palladium on carbon (20 mg, 10 wt%).  The flask was evacuated and 
backfilled with nitrogen twice, before being evacuated and backfilled with hydrogen twice.  The 
reaction was then stirred at room temperature under an atmosphere of hydrogen for 24 hours, and the 
crude product was filtered through Celite® and purified by flash column chromatography on silica 
gel (4:1  3:1 petroleum ether: ethyl acetate) to yield 2-(1H-indol-3-yl)phenol (119 mg, 85% yield) 
as a thick orange oil.  Rf = 0.29 (3:1 petroleum ether: ethyl acetate), 0.12 (4:1 petroleum ether: ethyl 
acetate);  1H NMR (300 MHz, CDCl3): δH = 8.31 (1H, br s, NH), 7.73 (1H, d, J = 8 Hz, Ar), 7.50 
(1H, dd, J = 7.5, 1.5 Hz, Ar), 7.45 – 7.31 (3H, m, Ar), 7.31 – 7.20 (2H, m, Ar), 7.19 – 7.08 (2H, m, 
Ar), 5.69 (1H, br s, OH);  13C NMR (75 MHz, CDCl3): δC = 153.2 (Ar, Cq), 136.3 (Ar, Cq), 130.9 (Ar, 
CH), 128.6 (Ar, CH), 126.2 (Ar, Cq), 123.4 (Ar, CH), 122.9 (Ar, CH), 121.1 (Ar, Cq), 120.7 (Ar, CH), 
120.5 (Ar, CH), 119.7 (Ar, CH), 115.5 (Ar, CH), 111.7 (Ar, CH); MS (ESI): m/z  208 ([M-H]-);  
HRMS found: [M+H]+ 210.0913, C14H11NO+H+ requires 210.0913. 
 
 
 
2-(Indolin-2-yl)phenol (24) 
To a flask containing glacial acetic acid (10 mL) was added compound 1 (1.0 mmol, 209 mg) and 
sodium cyanoborohydride (12.0 mmol, 754 mg), and the reaction was stirred at room temperature for 
26 hours.  The crude reaction was then quenched by careful addition of water (100 mL), before adding 
solid sodium hydroxide to pH ~12.  The crude reaction was extracted with ethyl acetate (3 × 20 mL), 
dried over MgSO4 and filtered.  The product was purified via flash column chromatography on silica 
gel (19:1 petroleum ether: ethyl acetate) to afford the title compound as a pale orange solid (92 mg, 
43% yield).  Rf =0.60 (3:1 petroleum ether: ethyl acetate), 0.16 (19:1 petroleum ether: ethyl acetate); 
1H NMR (300 MHz, CDCl3): δH = 9.75 (1H, br s, OH), 7.28 – 7.10 (3H, m, Ar), 7.06 (1H, d, J = 7.5 
Hz, Ar), 6.98 – 6.80 (4H, m, Ar), 4.92 (1H, dd, J = 12.5, 8.5 Hz, CH), 4.34 (1H, br s, NH), 3.38 – 
3.04 (2H, m, CH2); 13C NMR (75 MHz, CDCl3); δC = 156.88 (Cq, Ar), 148.7 (Cq, Ar), 130.8 (Cq, Ar), 
129.1 (CH, Ar), 128.5 (CH, Ar), 127.7 (CH, Ar), 124.9 (Cq, Ar), 124.8 (CH, Ar), 121.5 (CH, Ar), 
119.5 (CH, Ar), 117.6 (CH, Ar), 112.0 (CH, Ar), 65.6 (CH), 38.4 (CH2); MS (ESI): m/z  212 
([M+H]+). 
 2-(1H-Indol-2-yl)phenyl benzoate (25) 
Compound 1 (0.97 mmol, 202 mg), benzoyl chloride (1.16 mmol, 135 µL), triethylamine (1.46 mmol, 
203 µL) and DMAP (0.1 mmol, 12 mg) was stirred in CH2Cl2 (10 mL) at room temperature for 18 
hours.  Upon completion by TLC, the crude reaction was washed with 1M HCl (2 × 10 mL), water 
(10 mL) and brine (10 mL).  The crude reaction was purified via preparative liquid chromatography 
on silica gel (19:1 to 9:1 petroleum ether: ethyl acetate) to afford the title product as a yellow solid 
(141 mg, 47% yield).  M.p. 148 - 168 oC (decomposes);  Rf = 0.18 (9:1 petroleum ether: ethyl acetate);  
1H NMR (300 MHz, CDCl3): δH = 8.60 (1H, s, NH), 8.23 (2H, d, J = 7.5 Hz, Ar), 7.79 – 7.03 (11H, 
m, Ar), 6.83 (1H, s, Ar);  13C NMR (75 MHz, CDCl3): δC = 165.2 (C=O), 147.7 (Ar, Cq), 136.5 (Ar, 
Cq), 134.1 (Ar, CH), 133.7 (Ar, Cq), 130.3 (Ar, CH), 129.3 (Ar, Cq), 129.1 (Ar, CH), 129.0 (Ar, CH), 
128.8 (Ar, CH), 128.6 (Ar, Cq), 126.8 (Ar, CH), 125.9 (Ar, Cq), 123.8 (Ar, CH), 122.5 (Ar, CH), 
120.8 (Ar, CH), 120.1 (Ar, CH), 111.0 (Ar, CH), 102.8 (Ar, CH);  IR (neat, cm-1) ν = 1725 (C=O 
stretch), 1260 (C-O stretch); MS (ESI): m/z 314 ([M+H]+);  HRMS found: [M+H]+ 314.1184, 
C21H15NO2+H requires 314.1176. 
 
2-(1H-Indol-2-yl)phenyl acetate (26) 
Compound 1 (101.7 mg, 0.59 mmol), acetyl chloride (46 µL, 0.65 mmol), triethylamine (54 µL) and 
DMAP (6 mg, 0.05 mmol) were added to CH2Cl2 (5 mL) and stirred at room temperature for 16 h.  
The reaction was washed with 1 M HCl (3 × 5 mL), water (1 × 5 mL) and brine (1 × 5 mL), dried 
(MgSO4), filtered and the solvent was removed in vacuo.  The reaction was purified by flash column 
chromatography on silica gel (5:1 petroleum ether: ethyl acetate) to yield the title product as an off-
white solid (84.3 mg, 71% yield).  M.p. 112-127 oC; Rf = 0.23 (5:1 petroleum ether: ethyl acetate); 
1H NMR (300 MHz, CDCl3): δH = 8.50 (1H, s, NH), 7.70-7.62 (2H, m, Ar), 7.43-7.32 (3H, m, Ar), 
7.26-7.09 (3H, m, Ar), 6.78-6.82 (1H, m, Ar), 2.31 (3H, s, CH3); 13C NMR (75 MHz, CDCl3): δC = 
169.4 (C=O), 147.6 (Ar), 136.6 (Ar), 133.9 (Ar), 129.3 (Ar), 128.9 (Ar), 128.7 (Ar), 126.8 (Ar), 125.9 
(Ar), 123. 7 (Ar), 122.7 (Ar), 120.9 (Ar), 120.3 (Ar), 111.0 (Ar), 102.7 (Ar), 21.4 (CH3); IR (neat, 
cm-1) ν = 3357 (N-H stretch), 1735 (C=O stretch), 1368 (aromatic C-C stretch), 1220 (C-O stretch);  
MS (ESI): m/z 252 ([M+H]+);  HRMS found: [M+H]+ 252.1021, C16H13NO2+H+ requires 252.1019. 
 
2-(1H-Indol-2-yl)phenyl heptanoate (27) 
Compound 1 (0.92 mmol, 192 mg), heptanoyl chloride (1.10 mmol, 171 µL), triethylamine (1.38 
mmol, 192 µL) and DMAP (0.1 mmol, 12 mg) was stirred in CH2Cl2 (10 mL) at room temperature 
for 18 hours.  Upon completion by TLC, the crude reaction was washed with 1M HCl (2 × 10 mL), 
water (10 mL) and brine (10 mL).  The crude reaction was purified via preparative liquid 
chromatography on silica gel (19:1 to 9:1 petroleum ether: ethyl acetate) to afford the title product as 
a yellow solid (225 mg, 76% yield).  M.p. 51 - 54 oC;  Rf = 0.15 (9:1 petroleum ether: ethyl acetate);  
1H NMR (300 MHz, CDCl3): δH = 8.53 (1H, br s, NH), 7.70 – 7.61 (2H, m, Ar), 7.41 – 7.27 (3H, m, 
Ar), 7.25 – 7.10 (3H, m, Ar), 6.81 – 6.76 (1H, m, Ar), 2.59 (2H, t, J = 7.5 Hz, CH2), 1.70 (2H, pent, 
J = 7.5 Hz, CH2), 1.39 – 1.19 (6H, m, 3 × CH2), 0.87 (3H, t, J = 6.5 Hz, CH3);  13C NMR (75 MHz, 
CDCl3): δC = 172.4 (C=O), 147.6 (Ar, Cq), 136.5 (Ar, Cq), 134.0 (Ar, Cq), 129.4 (Ar, CH), 128.8 (Ar, 
CH), 128.7 (Ar, Cq), 126.7 (Ar, CH), 125.9 (Ar, Cq), 123.7 (Ar, CH), 122.6 (Ar, CH), 120.8 (Ar, CH), 
120.2 (Ar, CH), 111.0 (Ar, CH), 102.6 (Ar, CH), 34.7 (CH2), 31.5 (CH2), 28.9 (CH2), 24.9 (CH2), 
22.5 (CH2), 14.1 (CH3);  IR (neat, cm-1) ν = 1145 (C-O stretch), 1746 (C=O stretch), 2928 (C-H 
stretch);  MS (ESI): m/z 322 ([M+H]+);  HRMS found: [M+H]+ 322.1805, C21H23NO2+H requires 
322.1802. 
 
SRB Assay Procedure 
Short-term cell cultures (IN1472, IN1528, IN1760) were prepared from approximately 10mg of adult 
GBM biopsy tissue and maintained in Hams F10 nutrient mix [Invitrogen, Paisley UK] containing 
10% foetal calf serum in a 37 °C non-CO2 incubator as previously described.44 Passages 
of 10 to 14 were employed for the current study. In addition, we also employed U251 and U87 which 
are established GBM cell lines cultured under similar conditions. 
Treated cells were assessed for their capacity to proliferate following treatment 
with compounds using a sulphorhodamine B (SRB) assay.45 Briefly, 3000 cells were seeded per well 
in a 96 well plate and allowed to reach exponential growth (48 hours). Compounds were dissolved in 
DMSO [Sigma Aldrich; UK] and cells were treated for 72 hours with serial dilutions of the test 
compound.  The culture medium was removed and the cells fixed in 10% trichloroacetic acid [Sigma 
Aldrich; UK] on ice for 30 min followed by washing in water and air-drying. Cells were stained with 
0.4% sulforhodamine B [Sigma Aldrich; UK] prepared in 1% acetic acid for 15-20 mins, washed in 
1% acetic acid and air-dried. The dye was solubilized in 100 L of 10mM Tris (not buffered) and 
read at 560nm [Dynatech MR5000] for quantification. 
Analysis was performed using Sigmoidal Dose Response (Variable Slope) (Non-Linear Fit). 
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